Exon 20 Insertion Mutant EGFR Selective Inhibitor
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current EGFR inhibitors have limited selectivity for exon 20 insertion mutant EGFR, leading to insufficient therapeutic effects and increased side effects due to inhibition of wild-type EGFR, particularly in cancers with exon 20 insertion mutations such as non-small-cell lung cancer.
Innovation Solution
Development of specific compounds like (S)-N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizin-8-yl)acrylamide and its analogs, which exhibit high selectivity for exon 20 insertion mutant EGFR, reducing the inhibition of wild-type EGFR and enhancing therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If previously known EGFR inhibitors (gefitinib, erlotinib, afatinib) are administered to treat EGFR mutation-positive lung cancer, then high antitumor effect is achieved against exon 19 deletion mutant and L858R mutant EGFR, but side effects occur due to inhibition of wild-type EGFR and insufficient therapeutic effect against exon 20 insertion mutation
Solution Approach 1:
The patent applies local quality by designing a compound with specific structural features (quinoline ring at position 3, pyrrolidine or piperidine ring at position 4, and specific substituent patterns) that confer selective binding affinity to exon 20 insertion mutant EGFR while reducing interaction with wild-type EGFR. This localized structural optimization enables the compound to target the specific mutation site without broadly inhibiting all EGFR forms, thereby achieving high antitumor effect against exon 20 insertion mutations while minimizing side effects from wild-type EGFR inhibition.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters such as the type of substituent groups (e.g., -NR5aR5b, -OR5a, -SR5a), the position of substituents on the pyrrolidine or piperidine ring, and the specific configuration at chiral centers. These parameter variations are optimized to enhance selectivity for exon 20 insertion mutant EGFR. The compound formula (1) defines specific parameter ranges that achieve the desired balance between antitumor efficacy and reduced wild-type EGFR inhibition, directly addressing the contradiction between therapeutic effect and side effects.
2Productivity
If EGFR inhibitors are used to treat exon 20 insertion mutation-positive lung cancer, then treatment is provided, but therapeutic effects are insufficient compared to exon 19 deletion mutation or L858R mutation
Solution Approach 1:
The patent applies local quality by designing a compound with specific structural features (quinoline ring at position 3, pyrrolidine or piperidine ring at position 4, and specific substituent patterns) that confer selective binding affinity to exon 20 insertion mutant EGFR while reducing interaction with wild-type EGFR. This localized structural optimization enables the compound to target the specific mutation site without broadly inhibiting all EGFR forms, thereby achieving high antitumor effect against exon 20 insertion mutations while minimizing side effects from wild-type EGFR inhibition.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters such as the type of substituent groups (e.g., -NR5aR5b, -OR5a, -SR5a), the position of substituents on the pyrrolidine or piperidine ring, and the specific configuration at chiral centers. These parameter variations are optimized to enhance selectivity for exon 20 insertion mutant EGFR. The compound formula (1) defines specific parameter ranges that achieve the desired balance between antitumor efficacy and reduced wild-type EGFR inhibition, directly addressing the contradiction between therapeutic effect and side effects.
Data Source
AI summary
An antitumor agent comprising a compound selected from the group consisting of Compounds A to D described in the specification, or a salt thereof, for treating a malignant tumor patient expressing EGFR having exon 20 insertion mutation.